Page 58«..1020..57585960..7080..»

Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

Posted: May 27, 2024 at 2:49 am

We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalised ads. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Visit link:
Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine's Potential - Intelligent Living

Posted in Cell Medicine | Comments Off on Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% – openPR

Posted: May 27, 2024 at 2:48 am

Stem Cell Therapy Market

Read More: https://www.globenewswire.com/en/news-release/2023/11/17/2782506/0/en/Global-Stem-Cell-Therapy-Market-to-Reach-USD-928-6-Million-by-2031-Says-Allied-Market-Research.html

Stem Cell Therapy Market Statistics: The global Stem Cell Therapy market size is estimated to reach $928.6 million by 2031, growing at a CAGR of 16.2% from 2022 to 2031.

Stem Cell Therapy Market Growth Drivers:

Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions, has created a demand for innovative treatment options. Stem cell therapy offers potential solutions by promoting tissue regeneration and repair.

Advancements in Stem Cell Research: Continuous advancements in stem cell research, including the discovery of new cell sources, improved culturing techniques, and better understanding of stem cell behavior, have expanded the therapeutic applications of stem cell therapy. These advancements are driving the development of more effective and targeted treatment approaches.

Growing Aging Population: The global aging population is increasing, leading to a higher prevalence of age-related diseases and conditions. Stem cell therapy holds promise for addressing age-related degenerative disorders, such as osteoarthritis, Alzheimer's disease, and macular degeneration, by stimulating tissue repair and regeneration.

Favorable Regulatory Environment: Many countries are adopting supportive regulatory frameworks for stem cell therapy, which facilitate research, development, and commercialization of stem cell-based treatments. These regulations provide a conducive environment for companies and researchers to invest in stem cell therapy development.

Increasing Investments and Funding: There has been a surge in investments and funding for stem cell research and development from government bodies, private organizations, and venture capitalists. This financial support has accelerated the pace of research and clinical trials, leading to advancements in stem cell therapies.

Technological Advancements: Technological advancements, such as genetic engineering, tissue engineering, and 3D printing, have expanded the possibilities for stem cell therapy. These technologies enhance the precision, efficiency, and safety of stem cell-based treatments, opening new avenues for therapeutic applications.

Click To Get Sample Copy: https://www.alliedmarketresearch.com/request-sample/11317

The segments and sub-section of Stem Cell Therapy market is shown below:

By Cell Source: Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other

By Application: Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other

By Type: Allogeneic Transplants, Autologous Transplants

Some of the key players involved in the Market are: Allele Biotechnology and Pharmaceuticals, Astellas Pharma, Fujifilm Holding, Mesoblast, Novadip Biosciences, NuVasive, Orthofix, Smith & Nephew, Takeda Pharmaceutical, U.S. Stem Cell.

Important years considered in the Stem Cell Therapy study: Historical year - 2018-2022; Base year - 2022; Forecast period** - 2022 to 2032 [** unless otherwise stated]

If opting for the Global version of Stem Cell Therapy Market; then below country analysis would be included: - North America (USA, Canada and Mexico) - Europe (Germany, France, the United Kingdom, Netherlands, Italy, Nordic Nations, Spain, Switzerland and Rest of Europe) - Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, Southeast Asia and Rest of APAC) - South America (Brazil, Argentina, Chile, Colombia, Rest of countries etc.) - Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, Rest of MEA)

Key Questions Answered with this Study: 1) What makes Stem Cell Therapy Market feasible for long term investment? 2) How influencing factors driving the demand of Stem Cell Therapy in next few years? 3) Territory that may see steep rise in CAGR & Y-O-Y growth? 4) What geographic region would have better demand for product/services? 5) What opportunity emerging territory would offer to established and new entrants in Stem Cell Therapy market? 6) What strategies of big players help them acquire share in mature market? 7) Know value chain areas where players can create value? 8) What is the impact analysis of various factors in the Global Stem Cell Therapy market growth? 9) Risk side analysis connected with service providers?

Introduction about Stem Cell Therapy Market Stem Cell Therapy Market Size (Sales) Market Share by Type (Product Category) Stem Cell Therapy Market by Application/End Users Stem Cell Therapy Sales (Volume) and Market Share Comparison by Applications Global Stem Cell Therapy Sales and Growth Rate (2022-2032) Stem Cell Therapy Competition by Players/Suppliers, Region, Type, and Application Stem Cell Therapy (Volume, Value, and Sales Price) table defined for each geographic region defined. Stem Cell Therapy Players/Suppliers Profiles and Sales Data Key Raw Materials Analysis & Price Trends Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis ..and view more in complete table of Contents

Procure Complete Report@ https://www.alliedmarketresearch.com/checkout-final/139f33c6ac2962c73b01594c0c9673b5

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Contact Us: David Correa Portland, OR, United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com

About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.

Originally posted here:
Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% - openPR

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% – openPR

Study suggests approach for treating rare disorder – National Institutes of Health (NIH) (.gov)

Posted: May 27, 2024 at 2:48 am

At a Glance

Research into rare diseases and disorders is hampered by the limited number of people available to participate in studies. Many rare diseases and disorders also lack animal models that can help scientists perform early testing of new treatments.

One such rare disorder is Timothy syndrome. Problems with a single gene, called CACNA1C, cause this condition. CACNA1C codes for structures in cells called calcium channels. These help control signals throughout the brain and body. People with Timothy syndrome live with a range of severe symptoms including autism, epilepsy, and interruptions in the hearts normal electrical activity.

After the CACNA1C gene is transcribed into RNA, the RNA can be spliced in different ways to make different versions of the protein. Normally, splicing changes cause one version of the protein to be produced during development, and then another later on. In Timothy syndrome, the first version continues to be produced instead. As a result, calcium channels remain overactive, causing abnormal electrical activity in the bodys cells.

Researchers have been developing compounds called antisense oligonucleotides, or ASOs, to treat some rare genetic disorders. ASOs bind to small portions of RNA to affect how the RNA is processed. In a new study funded in part by NIH, a research team led by Dr. Sergiu Paca from Stanford University tested whether ASOs could block the changes in RNA that cause Timothy syndrome.

The team firstgrew 3D human brain tissue structures called organoids from stem cells donated by people with Timothy syndrome. The study was published on April 25, 2024, in Nature.

The researchers developed several ASOs that, in organoids grown to mimic the brains cerebral cortex, reduced the abnormal RNA splicing. Adding the two most promising ASOs to organoids derived from people with Timothy syndrome restored the functioning of calcium channels to normal levels.

To see whether the treatment could restore normal cell movements during brain development, the team created more complex structures called assembloids. These were made from different organoids fused together to mimic the human forebrain. Treating these assembloids with ASOs restored the normal movement of brain cells during development.

Timothy syndrome manifests during early development. To test how the ASOs might work in the developing brain, the researchers transplanted the human-derived organoids into the brains of newly born rats. The organoids integrated successfully into the growing brain tissue. When the researchers injected the rats with one of the ASOs, production of the abnormally spliced RNA was reduced. Calcium channels in the resulting cells worked more normally, and the cells looked normal under the microscope.

Our study showed that we can correct cellular deficits associated with Timothy syndrome, Paca says. We are now actively working towards translating these findings into the clinic, bringing hope that one day we may have an effective treatment for this devastating neurodevelopmental disorder.

Notably, the approach used in this study has potential for studying new treatments for other rare genetic disorders as well. Many challenges, however, still need to be solved before this technology could be used in the clinic.

References:Antisense oligonucleotide therapeutic approach forTimothysyndrome. Chen X, Birey F, Li MY, Revah O, Levy R, Thete MV, Reis N, Kaganovsky K, Onesto M, Sakai N, Hudacova Z, Hao J, Meng X, Nishino S, Huguenard J, Paca SP. Nature. 2024 Apr;628(8009):818-825. doi: 10.1038/s41586-024-07310-6. Epub 2024 Apr 24. PMID:38658687.

Funding:NIHs National Institute of Mental Health (NIMH); Stanford University; Autism Speaks, Inc.; Kwan Funds; Senkut Funds; Coates Foundation; Ludwig Family Foundation; Alfred E. Mann Foundation; New York Stem Cell Foundation; Chan Zuckerberg Initiative.

Read the original:
Study suggests approach for treating rare disorder - National Institutes of Health (NIH) (.gov)

Posted in Stem Cell Treatments | Comments Off on Study suggests approach for treating rare disorder – National Institutes of Health (NIH) (.gov)

A Revolutionary Approach to Flu Prevention: New Molecules Stop Infection Before It Starts – SciTechDaily

Posted: May 27, 2024 at 2:48 am

Scientists have developed novel drug-like molecules that could potentially prevent influenza infections by targeting the initial stage of the viral infection process. This represents a shift from traditional flu medications, which only treat after infection has occurred. The research indicates significant progress in the development of a preventative treatment for influenza, potentially reducing the need for annual vaccinations.

Currently, flu medications work by tackling the virus once it has already infected the body. However, researchers at Scripps Research and the Albert Einstein College of Medicine are taking a proactive approach. They have developed drug-like molecules aimed at preventing influenza infections before they start by blocking the initial stage of the viral infection process.

The drug-like inhibitors block the virus from entering the bodys respiratory cellsspecifically, they target hemagglutinin, a protein on the surface of type A influenza viruses. The findings, published on May 16, 2024, in the Proceedings of the National Academy of Sciences (PNAS), represent an important step forward in developing a drug that can prevent influenza infection.

Were trying to target the very first stage of influenza infection since it would be better to prevent infection in the first place, but these molecules could also be used to inhibit the spread of the virus after ones infected, says corresponding author Ian Wilson, DPhil, the Hansen Professor of Structural Biology at Scripps Research.

The inhibitors will need to be further optimized and tested before they can be assessed as antivirals in humans, but the researchers say that these molecules ultimately have the potential to help prevent and treat seasonal flu infections. And, unlike vaccines, the inhibitors likely wouldnt need to be updated yearly.

The scientists had previously identified a small molecule, F0045(S), with a limited capacity to bind and inhibit H1N1 type A influenza viruses.

We began by developing a high-throughput hemagglutinin binding assay that allowed us to rapidly screen large libraries of small molecules and found the lead compound F0045(S) with this process, says corresponding author Dennis Wolan, PhD, senior principal scientist at Genentech and former associate professor at Scripps Research.

Compound 7, a molecular inhibitor of the influenza virus, interacting with the influenza virus hemagglutinin protein. Credit: Scripps Research

In this study, the team aimed to optimize F0045(S)s chemical structure to design molecules with better drug-like properties and more specific binding ability to the virus. To start, the Wolan lab used SuFEx click-chemistry, which was first developed by two-time Nobel laureate and co-author K. Barry Sharpless, PhD, to generate a large library of candidate molecules with various tweaks to F0045(S)s original structure. When they screened this library, the researchers identified two molecules4(R) and 6(R)with superior binding affinity compared to F0045(S).

Next, Wilsons lab produced X-ray crystal structures of 4(R) and 6(R) bound to the flu hemagglutinin protein so that they could identify the molecules binding sites, determine the mechanisms behind their superior binding ability, and identify areas for improvement.

We showed that these inhibitors bind much more tightly to the viral antigen hemagglutinin than the original lead molecule did, says Wilson. By using click-chemistry, we basically extended the compounds ability to interact with influenza by making them target additional pockets on the antigen surface.

When the researchers tested 4(R) and 6(R) in cell culture to verify their antiviral properties and safety, they found 6(R) was non-toxic and had more than 200 times improved cellular antiviral potency compared to F0045(S).

Finally, the investigators used a targeted approach to further optimize 6(R) and develop compound 7, which proved to have even better antiviral ability.

This is the most potent small-molecule hemagglutinin inhibitor developed to date, says corresponding author Seiya Kitamura, who worked on the project as a postdoctoral fellow at Scripps Research and is now an assistant professor at the Albert Einstein College of Medicine.

In future studies, the team plans to continue to optimize compound 7 and to test the inhibitor in animal models of influenza.

In terms of potency, it will be hard to improve the molecule any further, but there are many other properties to consider and optimize, for example, pharmacokinetics, metabolism, and aqueous solubility, says Kitamura.

Because the inhibitors developed in this study only target H1N1 strains of influenza, researchers are also working to develop equivalent drug-like inhibitors to target other strains of influenza such as H3N2 and H5N1.

Reference: Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry by Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U. Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K. Barry Sharpless, Ian A. Wilson and Dennis W. Wolan, 16 May 2024, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2310677121

This work was supported by the NIH, the Nathan Shock Institute of Aging Research, and Einstein-Montefiore.

See the article here:
A Revolutionary Approach to Flu Prevention: New Molecules Stop Infection Before It Starts - SciTechDaily

Posted in Preventative Medicine | Comments Off on A Revolutionary Approach to Flu Prevention: New Molecules Stop Infection Before It Starts – SciTechDaily

Genetically engineered animals to be regulated by FDA – CSPI Newsroom

Posted: May 27, 2024 at 2:47 am

In May 2024, the FDA released guidance stating in effect that the agency will primarily be responsible for regulating genetically engineered animals. Heres what to know about gene-edited animals, labeling of GMO products, and what this means for consumers.

Humans have been shaping the genetics of plants and animals for millennia. Through selective breeding, humans choose to mate plants or animals possessing certain favorable traits to promote those traits in the population. While this technique only incrementally changes a populations traits, over many generations it can lead to drastic changes.

However, modern genetic engineering technologies allow scientists to directly induce targeted changes in an organisms DNA, allowing for much quicker and more precise changes in population-level traits. In recent decades, scientists have used genetic engineering to insert genes (i.e., portions of DNA) from one organism into another. And with newer gene-editing technologies such as CRISPR, scientists can even make narrowly targeted edits in a plant or animals DNA.

Food products derived from genetically modified plants have been sold in the US for decades. For example, the great majority of corn, soybeans, and cotton currently grown in the US are genetically modified. However, it is only within the last few years that genetically modified animals have been approved for commercial use. These animals are bioengineered to possess some desirable quality, such as faster growth or increased durability in response to environmental hazards.

In 2015, the FDA approved the first genetically engineered animal for commercial use in the US: AquAdvantage Salmon, which is a salmon modified to reach maturity more quickly than standard salmon. Since then, the FDA has approved other gene-edited animals for commercial purposes, including pigs that are less likely to induce allergic reactions that some humans have as a result of tick-borne illness. Other gene-edited animals are still in development, such as shorter-haired cows that are better able to withstand rising temperatures due to climate change.

But until recently, there was some controversy over which federal agency would be responsible for regulating genetically engineered animals.

The FDA announced in May 2024 that the agency will lead the charge on regulation of animals with intentional genomic alterations (IGAs). In its guidance, the FDA stated that the agency will consult with the USDA, but that the FDA will primarily be in charge of regulating these animals. Newly developed gene-edited animals will need to go through an oversight process, in which the agency will assess potential risks, before they can enter the market. Products that represent limited risk will receive proportionately less oversight.

For the past several years, it was unclear which agency, the FDA or the USDA, would regulate genetically engineered animals. CSPI argued in two op-eds, appearing in The Hill and STAT, that the FDA should be the agency to regulate these animals. For one, the FDAs mandate includes public health and animal health, while the USDAs mandate includes promoting the US agricultural industry and does not center human health. Additionally, while the USDA has oversight over some agricultural animalspoultry, cattle, horses, swine, and goatsthe FDA has authority over all others, so a system not centered on the FDA would be inefficient. Finally, the FDA has pre-existing experience in regulating genetically engineered animals, as well as the scientific resources and regulatory framework needed to effectively tackle regulation of these animals.

As CSPI President Dr. Peter G. Lurie stated, The FDAs scientific expertise and human and animal health mandates make it the appropriate agency to maximize the benefits and minimize the risks of the next generation of genetically altered animals.

Statement: Final guidance on regulation of genetically altered animals rightfully awards regulatory authority to FDA

Under federal law, manufacturers must disclose when their food products contain certain genetically modified ingredients. In July 2016, President Obama signed the National Bioengineered Food Disclosure Law (NBFDL), requiring food manufacturers to disclose the presence of bioengineered foods and ingredients.

Federal rules now require most foods and ingredients that have modified DNA to make a disclosure. The disclosure may be on the package or may require consumers to go to a website or make a telephone call. However, there are several exemptions to these disclosure rules, including for restaurant foods, small-scale manufacturers, and animals fed bioengineered crops. In addition, the disclosure will tell you that there are bioengineered ingredients but will not necessarily tell you which ingredients are bioengineered.

Moreover, not all animal-derived products are covered under the NBFDL. The rules do not apply to products that list meat, poultry, or eggs as their first ingredient (or their second ingredient after water, stock, or broth) because those product labels are regulated by other USDA statutes.

CSPI will continue to educate policymakers and the public about the benefits and risks associated with genetically engineered crops and animals. We will also continue to advocate for strong federal regulation of genetically engineered food products and press the biotechnology industry and farmers to use genetically engineered crops and animals in a sustainable manner.

Support CSPIs efforts to protect consumers

See the article here:
Genetically engineered animals to be regulated by FDA - CSPI Newsroom

Posted in Genetic Engineering | Comments Off on Genetically engineered animals to be regulated by FDA – CSPI Newsroom

FACT CHECK: Does genetically modified corn cause hypertension as Oyakhilome claims? – TheCable

Posted: May 27, 2024 at 2:47 am

Chris Oyakhilome, founder of LoveWorld Incorporated better known as Christ Embassy, has claimed that genetically modified corns cause hypertension.

In a live broadcast during a church programme, Oyakhilome warned the people to avoid genetically modified corn.

The clergyman claimed that most countries no longer produce local corn and that much of the corn sold in the markets has been genetically modified.

Im sure many of you who dont have an idea of organic corn. What it is. Dont think of the one youve been buying in the market, in your local market I mean. Dont think that one is really organic. Oyakhilome said.

Most countries dont have the original corn anymore. Its one of the earliest genetically modified crops, so most of what youve been eating is modified a long time ago.

Thats why you have to do something; you have to think again. The earlier you stop it, the better because no one is giving you this information. They are not telling you that the unexplained hypertension that your grandfather suffered with, that your father and granduncle suffered with, and that youre probably suffering with have something to do with corn.

Almost all the people Ive known that have high blood pressure all love corn and corn products but nobody ever told them that had anything to do with their problems.

The video has been shared by several posts on YouTube. It can be found here and here.

WHAT ARE GMOS?

Genetically Modified Organisms (GMO) are plants, animals, or microbes in which one or more changes have been made to the genome (DNA) through genetic engineering, in an attempt to alter its characteristics.

Genes can be introduced, enhanced, or deleted within a species, across species, or non-related species. Some examples of GM crops include Bt corn, soybeans, Bt potatoes, peanuts, Bt-sweet corn, Roundup Ready soybeans, Roundup Ready Corn, and Liberty Link corn.

Some of the objectives of developing genetically modified plants are to produce crops with enhanced characteristics which could be to improve crop protection by making them resistant to a particular disease and create higher-yield crops.

PROCESS OF GENETIC MODIFICATION OF CROPS

To transform a plant into a GMO plant, the gene that produces a genetic trait of interest is identified and separated from the other genetic material in a donor organism. It is then transferred into a plant cell. A donor organism may be a bacterium, fungus, or another plant. In the case of Bt corn, the donor organism is a naturally occurring soil bacterium Bacillus thuringiensis (Bt).

The maize variant has Bt genes that provide protection against some insects and help the maize plant tolerate moderate drought. Bt corn prevents crop damage by reducing the need for spraying insecticides.

One of the methods used to transfer DNA is to coat the surface of small metal particles with the relevant DNA fragment and bombard the particles into the plant cells using the gene gun method.

The gene gun introduces the DNA directly into plant cells containing cell walls. The gene gun is used to bombard the plant cell wall with many DNA-coated metal particles by using compressed helium as the propellant.

The metal particles commonly used for gene gun bombardment include gold, tungsten, palladium, rhodium, platinum, and iridium. They are coated with DNA, accelerated by helium gas, and bombard the plant cells.

The metal particles punch holes in, pass through the cell wall, and enter the plant cells, leaving the DNA cargo inside the cells.

An alternative method is through the use of a bacterium or virus. The bacterium most frequently used for genetically modified crops is the Agrobacterium Tumefaciens. The gene of interest is transferred into the bacterium and the bacterial cells then transfer the new DNA to the genome of the plant cells. The plant cells that take up the DNA are then grown to create a new plant with new characteristics.

In January, the federal government approved the commercial release and open cultivation of four Tela Maize varieties a high-yielding maize variety, developed by the Institute of Agricultural Research (IAR) in partnership with the African Agricultural Technology Foundation (AATF).

The maize variety has been genetically engineered for improved insect resistance and drought tolerance to boost farmers yield and also ensure food security. GM corn is used for foods, drinks, and livestock feed.

DOES GENETICALLY MODIFIED CORN CAUSE HYPERTENSION?

Discussions and concerns have been raised over the effects of genetically modified crops on health. While some studies suggest that genetically modified crops may have health implications for humans, other researches argue that these crops are unharmful to human health and provide some nutrients like their conventional counterparts.

However, the US Food and Drug Administration (FDA) said GMO foods are as healthy and safe to eat as their non-GMO counterparts.

According to the World Health Organisation (WHO), genetically modified foods currently available on the international market have passed safety assessments and are not likely to present risks to human health.

The health organisation also said no effects on human health have been shown as a result of the consumption of such foods by the general population in the countries where they have been approved.

According to WHO, Hypertension (also known as high blood pressure) is when the pressure in the blood vessels is higher than normal.

The risk factors of hypertension include unhealthy diets (high salt consumption, a diet high in saturated fat and trans fats), physical inactivity, being overweight, and excess alcohol intake. Other factors include genetics/family history of hypertension and aging.

It is recommended that hypertension be diagnosed when a persons systolic blood pressure (SBP) is greater than 140 mm Hg and/or their diastolic blood pressure (DBP) is greater than 90 mm Hg following repeated examination ((140/90 mmHg or higher).

TheCable spoke with Jerome Mafeni, technical director at the Network for Health Equity and Development (NHED), to confirm if there are studies that suggest genetically modified corn causes hypertension.

Mafeni said at the moment, there is no scientific study that says GM corn causes hypertension, but noted that there might be the likelihood of reactions to such food items over time.

There is no scientific study that suggests such. Because they (TELA maize) are just coming into the country, it will take a much longer time to conduct a study to be able to prove any linkage between GMO foods and health conditions, Mafeni said.

That said, the fact that they are genetically modified means that there might be the possibility that people who consume GMO foods may have reactions to those foods without knowing. But that is yet to be verified.

TheCable also reached out to Bukola Odele, a food and nutrition scientist. Odele noted that corn is made up of carbohydrates, adding that hypertension is caused by excessive salt intake.

Before now, I dont think we consume GM corn in Nigeria and the one we know about was approved in January as a test run. If you even check that, saying that our grandfathers died as a result of that through hypertension is false, Odele said.

I think they even had better blood pressure than that of our current generation and that is because they often ate more fresh meals from the farm, while in this generation, people are consuming a whole lot of processed foods.

Industries are flooding the market with convenience, easy-to-make foods that have very low nutritional value and adverse effects on health. A lot of these processed foods contain a lot of salt, sugar, or fat. And when you have these in excess, they always have health implications.

About corn, naturally occurring foods contain sodium but in low quantities. These low quantities are also in healthy quantities. The moment the sodium we consume is from processed food items, thats when it becomes an issue. If youre thinking of what genetically modified corn would cause, the first thing you would look at is not even hypertension but diabetes. So far, I havent found any evidence that links GM corn to hypertension. I know that the largest cause of hypertension is high sodium intake from most of the processed food we consume.

Agnes Asagbra, the director-general of the National Biosafety Management Agency (NBMA), told TheCable that the approved TELA maize went through a thorough assessment before it was recommended for commercialisation.

We regulate the activities of modern biotechnology. In the course of our work, we ensure due diligence before any permit is granted. We have granted three permits so far for commercialisation of cowpea, BT cotton for textiles, and Tela maize, she said.

Before those approvals were granted, they went through a series of rigorous risk assessments.

We do our risk assessments, we dont do it independently but with sister agencies like the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria Agricultural Quarantine Service (NAQS), and other relevant agencies including the academia, NGOs, and research institutes. We bring them all together to review these permutations thoroughly.

So far, the Tela maize that has been approved is not even in the market and has not been launched. This is the first GM corn that will be commercially released in Nigeria.

The risk assessment that we have carried out declared the crop safe and there is no scientific evidence that links GM corn to hypertension. We have done our due diligence and it is safe, as safe as its conventional counterpart.

Also speaking, Olusina Ajidahun, an internal medicine physician, said: There are no studies to show that GM corn increases your risk of hypertension. This particular claim is not backed scientifically.

We are having an increase in the rise of genetically modified foods and we know for sure that some genetically modified foods can increase the risk of toxic effects on organs like the liver, heart, pancreas, and kidney. Studies are still trying to correlate the linkage of GM foods to cancer.

Theres no scientific evidence that taking GM corn increases the risk of having hypertension. One thing about hypertension is that it is multifactorial, it could be a result of genetics, lifestyle, or a lot of things. Coincidentally, it might be the case where these people are hypertensive and for some reason, they just like corn.

VERDICT

Theres no scientific evidence to support the claim that genetically modified corn causes hypertension as claimed by Oyakhilome.

More here:
FACT CHECK: Does genetically modified corn cause hypertension as Oyakhilome claims? - TheCable

Posted in Genetic Engineering | Comments Off on FACT CHECK: Does genetically modified corn cause hypertension as Oyakhilome claims? – TheCable

Monopar Announces CFO Succession

Posted: May 27, 2024 at 2:47 am

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring.

See the original post:
Monopar Announces CFO Succession

Posted in Global News Feed | Comments Off on Monopar Announces CFO Succession

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Posted: May 27, 2024 at 2:47 am

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.

Here is the original post:
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Posted in Global News Feed | Comments Off on Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

Posted: May 27, 2024 at 2:47 am

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada.

View original post here:
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

Posted in Global News Feed | Comments Off on IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

Posted: May 27, 2024 at 2:47 am

PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex.

Read the original here:
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

Posted in Global News Feed | Comments Off on Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

Page 58«..1020..57585960..7080..»